These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23194297)

  • 21. Effective prediction model and determination of binding residues influential for inhibitors targeting HIV-1 integrase-LEDGF/p75 interface by employing solvent accessible surface area energy as key determinant.
    Thangsunan P; Wongsaipun S; Kittiwachana S; Suree N
    J Biomol Struct Dyn; 2020 Feb; 38(2):460-473. PubMed ID: 30744499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis.
    Xue W; Jin X; Ning L; Wang M; Liu H; Yao X
    J Chem Inf Model; 2013 Jan; 53(1):210-22. PubMed ID: 23231029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Study on the interactions between diketo-acid inhibitors and prototype foamy virus integrase-DNA complex via molecular docking and comparative molecular dynamics simulation methods.
    Hu JP; He HQ; Tang DY; Sun GF; Zhang YQ; Fan J; Chang S
    J Biomol Struct Dyn; 2013; 31(7):734-47. PubMed ID: 22913375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein.
    Hayouka Z; Hurevich M; Levin A; Benyamini H; Iosub A; Maes M; Shalev DE; Loyter A; Gilon C; Friedler A
    Bioorg Med Chem; 2010 Dec; 18(23):8388-95. PubMed ID: 20974536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 1,2,3,4-Tetrahydroisoquinolines as inhibitors of HIV-1 integrase and human LEDGF/p75 interaction.
    George A; Gopi Krishna Reddy A; Satyanarayana G; Raghavendra NK
    Chem Biol Drug Des; 2018 Jun; 91(6):1133-1140. PubMed ID: 29405651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of novel 3-hydroxypicolinamides as selective inhibitors of HIV-1 integrase-LEDGF/p75 interaction.
    Zhang FH; Debnath B; Xu ZL; Yang LM; Song LR; Zheng YT; Neamati N; Long YQ
    Eur J Med Chem; 2017 Jan; 125():1051-1063. PubMed ID: 27810592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Advances in the Development of Small-Molecular Inhibitors Target HIV Integrase-LEDGF/p75 Interaction.
    Zhao Y; Luo Z
    Mini Rev Med Chem; 2015; 15(14):1195-208. PubMed ID: 26156421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization.
    Christ F; Shaw S; Demeulemeester J; Desimmie BA; Marchand A; Butler S; Smets W; Chaltin P; Westby M; Debyser Z; Pickford C
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4365-74. PubMed ID: 22664975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study of Structure-active Relationship for Inhibitors of HIV-1 Integrase LEDGF/p75 Interaction by Machine Learning Methods.
    Li Y; Wu Y; Yan A
    Mol Inform; 2017 Jul; 36(7):. PubMed ID: 28244220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a novel 5-carbonyl-1H-imidazole-4-carboxamide class of inhibitors of the HIV-1 integrase-LEDGF/p75 interaction.
    Serrao E; Xu ZL; Debnath B; Christ F; Debyser Z; Long YQ; Neamati N
    Bioorg Med Chem; 2013 Oct; 21(19):5963-72. PubMed ID: 23985689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kuwanon-L as a New Allosteric HIV-1 Integrase Inhibitor: Molecular Modeling and Biological Evaluation.
    Esposito F; Tintori C; Martini R; Christ F; Debyser Z; Ferrarese R; Cabiddu G; Corona A; Ceresola ER; Calcaterra A; Iovine V; Botta B; Clementi M; Canducci F; Botta M; Tramontano E
    Chembiochem; 2015 Nov; 16(17):2507-12. PubMed ID: 26360521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based virtual screening toward the discovery of novel inhibitors for impeding the protein-protein interaction between HIV-1 integrase and human lens epithelium-derived growth factor (LEDGF/p75).
    Panwar U; Singh SK
    J Biomol Struct Dyn; 2018 Sep; 36(12):3199-3217. PubMed ID: 28948865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential interaction of HIV-1 integrase and JPO2 with the C terminus of LEDGF/p75.
    Bartholomeeusen K; De Rijck J; Busschots K; Desender L; Gijsbers R; Emiliani S; Benarous R; Debyser Z; Christ F
    J Mol Biol; 2007 Sep; 372(2):407-21. PubMed ID: 17669426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The selenium-containing drug ebselen potently disrupts LEDGF/p75-HIV-1 integrase interaction by targeting LEDGF/p75.
    Zhang DW; Yan HL; Xu XS; Xu L; Yin ZH; Chang S; Luo H
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):906-912. PubMed ID: 32228103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of the LEDGF/p75 binding site in HIV-1 integrase.
    Busschots K; Voet A; De Maeyer M; Rain JC; Emiliani S; Benarous R; Desender L; Debyser Z; Christ F
    J Mol Biol; 2007 Feb; 365(5):1480-92. PubMed ID: 17137594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [LEDGF/p75: a novel target for anti-HIV therapy and advances in the study of its related inhibitors].
    Chen WM; Liu XY
    Yao Xue Xue Bao; 2009 Sep; 44(9):953-60. PubMed ID: 20055168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75.
    Du L; Zhao Y; Chen J; Yang L; Zheng Y; Tang Y; Shen X; Jiang H
    Biochem Biophys Res Commun; 2008 Oct; 375(1):139-44. PubMed ID: 18691555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular dynamics simulations of the HIV-1 integrase dimerization interface: guidelines for the design of a novel class of integrase inhibitors.
    Sippel M; Sotriffer CA
    J Chem Inf Model; 2010 Apr; 50(4):604-14. PubMed ID: 20230013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a flavonoid library for inhibition of interaction of HIV-1 integrase with human LEDGF/p75 towards a structure-activity relationship.
    Yin ZH; Yan HL; Pan Y; Zhang DW; Yan X
    Ann Med; 2022 Dec; 54(1):1590-1600. PubMed ID: 35658757
    [No Abstract]   [Full Text] [Related]  

  • 40. Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage.
    Le Rouzic E; Bonnard D; Chasset S; Bruneau JM; Chevreuil F; Le Strat F; Nguyen J; Beauvoir R; Amadori C; Brias J; Vomscheid S; Eiler S; Lévy N; Delelis O; Deprez E; Saïb A; Zamborlini A; Emiliani S; Ruff M; Ledoussal B; Moreau F; Benarous R
    Retrovirology; 2013 Nov; 10():144. PubMed ID: 24261564
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.